Prudden Holly J, Tatoud Roger, Janes Holly, Wallace Stephaun, Miller Veronica, Bekker Linda-Gail, Donnell Deborah
HIV Programmes and Advocacy, International AIDS Society, Geneva, Switzerland.
Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
AIDS Res Hum Retroviruses. 2024 May;40(5):301-307. doi: 10.1089/AID.2022.0150. Epub 2023 Sep 4.
The challenge of designing future HIV prevention efficacy trials in a rapidly evolving HIV prevention landscape was explored through a series of virtual stakeholder's engagement meetings convened online between October 2020 and April 2021. A broad array of stakeholders from the HIV prevention research community reviewed current trial designs and lessons learned, explored issues specific to unique product classes, and concluded with specialist-focused examinations of statistical design concepts and the importance of community engagement in research. The aim was to reflect on current approaches and evaluate new trial design approaches for evaluating efficacy of a candidate prevention strategy in the context of an active-controlled trial, which does not include a placebo arm. In this report, we provide a summary of the discussion points that included gaps in understanding and logical next steps in the prevention research pathway. The technical challenges involved in the statistical design approaches are described in a companion article.
通过2020年10月至2021年4月在线召开的一系列虚拟利益相关者参与会议,探讨了在快速发展的艾滋病预防领域设计未来艾滋病预防疗效试验所面临的挑战。艾滋病预防研究界的广泛利益相关者审查了当前的试验设计和经验教训,探讨了独特产品类别的特定问题,并以针对统计设计概念和社区参与研究的重要性的专家重点审查作为结束。目的是反思当前方法,并评估在不包括安慰剂组的活性对照试验背景下评估候选预防策略疗效的新试验设计方法。在本报告中,我们总结了讨论要点,其中包括预防研究途径中的理解差距和合理的下一步措施。统计设计方法所涉及的技术挑战在一篇配套文章中进行了描述。